Trials / Completed
CompletedNCT02630823
MK-3475 Immunotherapy in Endometrial Carcinoma
Immunotherapy With MK-3475 in Surgically Resectable Endometrial Carcinoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Due to the high expression of PD-L1 in endometrial cancers as well as in ovarian cancers which are molecularly similar to uterine serous cancers, using pembrolizumab should be beneficial in this patient population. Since the investigators are able to get a pre-treatment research- related endometrial biopsy as well as the surgical specimen post two cycles of pembrolizumab, the investigators will be able to evaluate the mechanism of action of this drug on the endometrial cancer tumor environment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-3475 | |
| PROCEDURE | Surgical resection (standard of care) | |
| DRUG | Paclitaxel (standard of care) | |
| DRUG | Carboplatin (standard of care) | |
| RADIATION | Radiation (standard of care) | |
| PROCEDURE | Endometrial biopsy | |
| PROCEDURE | Peripheral blood draw |
Timeline
- Start date
- 2016-02-05
- Primary completion
- 2019-01-01
- Completion
- 2020-10-03
- First posted
- 2015-12-15
- Last updated
- 2025-01-03
- Results posted
- 2025-01-03
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02630823. Inclusion in this directory is not an endorsement.